Efficacy and Safety of Super-Selective Bronchial Arterial Infusion Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

Abstract

<b><i>Objective:</i></b> The objective was to study the effectiveness and safety of super-selective bronchial arterial infusion (SBAI) chemotherapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). <b><i>Methods:</i></b> The clinical data of 120 advanced NSCLC patients were retrospectively analyzed. Among them, 60 NSCLC patients were treated with SBAI method, another 60 NSCLC patients received systemic intravenous chemotherapy as the control group. The efficacy and safety between two groups of patients were compared. <b><i>Results:</i></b> The objective response rate and disease control rate of NSCLC patients treated with SBAI were significantly higher than those of the control group (<i>p</i> &#x3c; 0.05). The 3-month progression-free survival (PFS) rate (96.67%) and 6-month PFS rate (86.67%) of the SBAI group were significantly higher than those of the control group (73.33% and 56.67%) (<i>p</i> &#x3c; 0.01). After treatment, the FACT-L scores of patients in the SBAI group were significantly higher than those of the control group (<i>p</i> &#x3c; 0.05). The scores of all the 13 core symptom items and six symptom interference items of NSCLC patients in the SBAI group were lower than those of the control group (<i>p</i> &#x3c; 0.05). The adverse reactions rate in the SBAI group were significantly lower than those in the control group (<i>p</i> &#x3c; 0.05). <b><i>Conclusion:</i></b> The short-term efficacy of SBAI chemotherapy for advanced NSCLC is significantly higher than that of traditional peripheral intravenous chemotherapy, and it can significantly improve patients’ quality of life and reduce the incidence of adverse reactions.